SMAD4 (Pancreatic Adenocarcinoma Marker)

Antibody with azide: store at 2 to 8 degree C.<br>Antibody without azide: store at -20 to -80 degree C.<br>Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF- family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. SMAD4 is absent in approximately 80% of pancreatic adenocarcinoma, but rarely in endometrial, colorectal, ovarian, lung, breast adenocarcinomas, and malignant melanom. SMAD4 is an important marker for confirming a pancreatic adenocarcinoma. Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival than SMAD4 negative patients.

[mothers against decapentaplegic homolog 4; Mothers against decapentaplegic homolog 4; mothers against decapentaplegic homolog 4; SMAD family member 4; Deletion target in pancreatic carcinoma 4; SMAD family member 4]